CHARLESTON, S.C., Jan. 12, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP) is happy to report that it has received notice that Investigational Review Board (IRB) approval has been granted this month to the Philadelphia College of Osteopathic Medicine for the research project application titled 'Characterization of Intracranial Hemorrhages by Color MRI Automatic Segmentation,' by Dr. H. Keith Brown and his collaborators. With this new approval, the team of research scientists and clinicians will now begin collecting and analyzing diagnostic images from cases of intracranial hemorrhages using RevColor™, Rev3D™, and RevDisplay™ MRI software. The results of this important clinical study will be presented at scientific sessions throughout the country and submitted for publication in an appropriate medical image analysis related journal later this year.

This study along with the earlier work reported on August 16^th 2010 on the 'Characterization of intracranial masses by color MRI automatic segmentation,' will be the basis for new developments targeting the characterization of head trauma injuries and brain tumors. Several important applications may be developed such as the detection and characterizing of sports injuries due to head trauma or concussions.

Tom O'Brien, President of Revolutions Medical, states, "It is great to see continued serious work being done with our proprietary color MRI software platform. Finally seeing key applications for the brain being performed by such credible scientific researchers gain traction, reinforces my belief that we are still on schedule to launch our first software as a service product for applications the second half of this year. This is just the beginning as interest continues to build for other clinical applications for our MRI software tools with various collaborators."

About Revolutions Medical Corporation

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved), safety blood drawing device; and the RevColor^TM, RevDisplay^TM and Rev3D^TM software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS) preliminary called RevTrack (FDA approved).

For additional information, please visit Revolutions Medical corporate website: http://www.revolutionsmedical.com

To be added to the Revolutions Medical investor email list, please email www.globenewswire.com/newsroom/ctr%3Fd=191624%26l=13%26a=Skey%2540revolutionsmedical.com%26u=mailto%253ASkey%2540revolutionsmedical.com">Skey@revolutionsmedical.com with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook -- visit www.Facebook.com/Revmed" target="_top" rel="nofollow">http://www.Facebook.com/Revmed

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.